Rating Scale devised for HSP

The Spastic Paraplegia Rating Scale – a reliable and valid measure of disease severity

Dr Rebecca Schüle

(Editor’s Note, Oct. 2018: Rebecca Schüle, driving force behind the creation and development of the SPRS, is a member of the Clinical Trial team associated with the HSP Research Program that is facilitated and funded by this Foundation.)

 

The clinical Spastic Paraplegia Rating Scale (SPRS) measures disease severity and progression over time.

 

The SPRS will be the primary outcome measure for the upcoming Phase 2a clinical trial, where the aim is to make a preliminary determination on the effectiveness of Noscapine as a treatment for SPG4 HSP.

 

In 2003 the German Network for Hereditary Movement Disorders (GeNeMove) was founded to research rare genetic movement disorders in Germany.  The SPRS is the result of a collaboration between movement disorder specialists – the GeNeMove SP task force – from six German universities.  Sixty-three patients from 50 families were recruited for the trial in seven GeNeMove SP outpatient clinics.  The rating requires less than 15 minutes to complete and requires no special equipment, so it is suitable in an outpatient setting.

Scientifically rigorous and clinically meaningful rating scales are essential to measure treatment impact, especially in diseases in which conventional laboratory markers of disease activity are missing, which is the case with HSP.

The full article is available at:

http://www.neurology.org/content/vol67/issue3/

Scroll down the page until you locate “The Spastic Paraplegia Rating Scale (SPRS): a reliable and valid measure of disease severity” and choose from the options offered.

View the contents of the SPRS

The scale is presented here in image form – just click on an image to see it full-size:

SPRS page 1
SPRS page 2
SPRS page 3

.

.

.

.

.

.

.

.

.

.

 

SOURCE: Neurology. 2006 Aug 8;67(3):430-4

The Spastic Paraplegia Rating Scale (SPRS): a reliable and valid measure of disease severity

Schüle R, Holland-Letz T, Klimpe S, Kassubek J, Klopstock T, Mall V, Otto S, Winner B, Schöls L.

Hertie Institute for Clinical Brain Research and Department of Neurology, Eberhard Karls University,
Tubingen, Germany.